Outlook Therapeutics Inc (STU:41O) Stock Price, Trades & News

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Financial Strength

1/10

Name	Current	Vs Industry
Cash-To-Debt	0.29
Equity-to-Asset	-1.32
Debt-to-Equity	-0.94
Debt-to-EBITDA	-0.44
Piotroski F-Score	3/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	-48.1	Distress Grey Safe
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year EBITDA Growth Rate	33
	3-Year EPS without NRI Growth Rate	21.3
	3-Year FCF Growth Rate	34.7
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	56.02
	Future 3-5Y Total Revenue Growth Rate Estimate	151.74

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	49.51
	9-Day RSI	54.89
	14-Day RSI	59.33
	3-1 Month Momentum %	386.88
	6-1 Month Momentum %	119.29
	12-1 Month Momentum %	-38.48

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.54
	Quick Ratio	0.45
	Cash Ratio	0.2
	Days Inventory	851.05
	Days Sales Outstanding	1670.26
	Days Payable	2341.67

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-68
	Shareholder Yield %	-19.18

Profitability Rank

	Name	Current	Vs Industry		Vs History
	Gross Margin %	-361.75
	Operating Margin %	-18245.48
	Net Margin %	-18360.54
	EBITDA Margin %	-18698.49
	FCF Margin %	-13243.28
	OCF Margin %	-13243.28
	ROA %	-304.23
	ROIC %	-236.68
	3-Year ROIIC %	-11.64
	ROC (Joel Greenblatt) %	-27618.56
	Moat Score	3
	Tariff Resilience Score	4

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	74.52
	EV-to-EBIT	-4.05
	EV-to-EBITDA	-4.06
	EV-to-Revenue	758.97
	EV-to-Forward-Revenue	3.3
	EV-to-FCF	-5.36
	Earnings Yield (Greenblatt) %	-24.69
	FCF Yield %	-20.23

GF Value™

STU:41O

Warning Signs

Warning! GuruFocus detected 5 Severe warning signs with 41O. Try a 7-Day Free Trial to check it out.

Outlook Therapeutics Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Outlook Therapeutics Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Annual report for 2026	2026-12-18	In 157 days
Fourth quarter earnings results for 2026	2026-12-18	In 157 days
Third quarter earnings results for 2026	2026-08-14	In 31 days
Second quarter earnings results for 2026	2026-05-15	0.20 (+3.17%)
General meeting for 2026	2026-03-10 09:00	0.36 (+4.08%)
First quarter earnings results for 2026	2026-02-17	0.40 (-1.84%)
Annual report for 2025	2025-12-19	1.89 (+0.00%)
Fourth quarter earnings results for 2025	2025-12-19	1.89 (+0.00%)
Piper Sandler 37th Annual Healthcare Conference	2025-12-02 10:00	1.57 (+4.11%)
Third quarter earnings results for 2025	2025-08-14	1.74 (+0.00%)

Show

Entries

Press Release

	Subject	Date
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outlook Therapeutics, Inc. - OTLK	2024-12-02
	OTLK FINAL DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK	2024-01-02
	SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming Deadline	2024-01-02
	OTLK DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action -- OTLK	2024-01-01
	OUTLOOK DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Outlook Therapeutics, Inc. and Encourages Investors to Contact the Firm	2023-12-29
	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OTLK	2023-12-28
	OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit	2023-12-28
	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Outlook Therapeutics, Inc. (OTLK)	2023-12-28
	SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming Deadline	2023-12-27
	ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK	2023-12-26

10/Page

Articles on Outlook Therapeutics Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.